ARTHEx BIOTECH

Muscular dystrophies are a group of degenerative genetic conditions that gradually weaken the muscles and lead to progressive disability. Myotonic dystrophy (DM1) is the most common muscular dystrophy in adults and is a highly disabling disease with symptoms involving skeletal musculature, heart and nervous system.

ARTHEx Biotech S.L. is a University of Valencia' spin-off company focused on the development of a treatment against type 1 muscular dystrophy, which is based on microRNA inhibitors. The proof of concept of the efficacy of these molecules in animal models  was generated in the translational genomics laboratory of the University of Valencia, directed by Dr. Ruben Artero.

The founders of this company are Dr. Beatriz Llamusí and Dr. Ruben Artero. The business model proposed to complete this project corresponds to the current open innovation model, in which the biotechnology company that emerges from a research center develops the products until clinical phase 2 (efficacy), and then it licenses them to pharmaceutical multinationals with the ability to complete the development, more advanced studies and marketing.

The information contained in this business data sheep has been provided by the company and the University of Valencia Science Park Foundation (FPCUV) is not responsible for its content.